B-Phage
About your organization / profile
B-Phage is a biotech startup dedicated to combating the antimicrobial resistance (AMR) crisis, by isolating bacteriophages and leveraging AI technology, to ultimately develop innovative therapeutics.
The problem: AMR could cause 10 million deaths annually and cost $100 trillion by 2050.
Our solution: Bacteriophage therapy.
B-Phage R&D: A phage-host biorepository, supported by a computational platform to predict phage-host interactions, leveraged to develop phage therapeutics.
Market opportunity: The AMR therapeutics market, valued at >$8 billion.
Pipeline: Preclinical testing --> phase I – III clinical trials --> phage therapeutic product to market.
Capital requirements: $ 2 million, for preclinical testing of E. coli phages to treat urinary tract infections (UTIs).
Network (0)
There are no organizations in the network.
Recent activities
B-Phage has updated its fundraising.
B-Phage has published fundraising documents.
Naadira Vanker has joined B-Phage.